Seeking Alpha

Big Pharma firms, NIH to join up to study major diseases

  • Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.
  • In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.
  • The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).
  • Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
Comments (4)
  • theo_rhetoric
    , contributor
    Comments (166) | Send Message
    Collaboration has produced some of the greatest leaps in solutions. This is the kind of leadership I desire from my government.
    4 Feb, 08:45 AM Reply Like
  • RWMostow
    , contributor
    Comments (1436) | Send Message
    I do not see cancer on the list. What happened?


    4 Feb, 09:07 AM Reply Like
  • jameswparker
    , contributor
    Comments (13) | Send Message
    No major progress has been made in the treatment of these 4 diseases. Sharing & collaboration could move the pharmaceutical companies forward by decades in less than 5 yrs.
    4 Feb, 11:16 AM Reply Like
  • BlueOkie
    , contributor
    Comments (5577) | Send Message
    Since when has the gov't got involved in something besides defense and improved upon it. If they find a cure, who develops the drug? You still have FDA. What exactly does NIH bring to the party.
    4 Feb, 12:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector